In the near future, plans for the Department include the development of three core facilities which will act in tandem to fuel performance in the Department.

1)    The first core facility will be performing Immunodiagnosis of endemic diseases and their consecutive complications with high quality including: development and commercialization of immunodiagnostic kits for endemic diseases by employment of our MAb in different diagnostic techniques such as sandwich ELISA, nanoparticle-modified sandwich ELISA, and new kit gold nanoparticle in an immunostrip assay.

2)    The second core facility will be enforcement and developing a suitable environment for research in the following fields:

-      Immunohistochemistry.

-      Tissue Culture including:

·     Tissue engineering.

·     Stem cell research

·     Monoclonal antibody production.

·     Production of cell lines.

-      Nanotechnology.

-      Molecular biology.

-      Assessment of cytotoxicity of different anticancer compounds.

3)    The third core facility is providing training courses for Egyptian and non-Egyptian trainees interested in MAb production, cell culture, and other associated techniques.


 The mission of the Immunology Department is the development of a research environment in which a broad range of interdisciplinary work is carried out to cope with the new era of the Immunology and stem cell biology.

 In particular, the Department targets:

  •  The immunodiagnosis of endemic diseases (viral and parasitic), the assessment of immune response to endemic infections and their associated  morbidity changes, and tackling immunological approaches for the management of endemic diseases and their hepatic and urinary complications.

  Former Heads And Staff Members

Former Heads 

Emeritus Prof. Zeinab Ahmed Shaker

Emeritus Prof. Hanaa Ismail Hassanein

Late Prof. Azza El Bassiouny

Emeritus Prof. Zeinab Abou Bakr Demerdash

Emeritus Prof.  Kesmat Mohamed Maher

Emeritus Prof. Faten Salah El-Din Mahmoud

Emeritus Prof. Faten Moustafa Nagy


Staff Members

Emeritus Prof. Moustafa Abdel Haleem Kadah

Emeritus Prof. Hanan Mohamed Gamal El-Din El-Baz

Emeritus Prof.  Mohamed Youssef Mohamed El-Mohandes

Emeritus Prof.  Manal Mohamed Kamel

Emeritus Prof.  Salwa Hassan Mohamed

Emeritus Prof.  Mona Mohamed Kamel Zoheiry

Emeritus Prof.  Wafaa Abd El Fattah Mansour

Researcher Marwa Hassan Mohammed

Researcher Shimaa Attiah Hassan

Researcher Sarah Maher

Associate Researcher Engy Mohsen Abdel-Moniem

Associate Researcher Ali Ahmed Baioumi

Associate Researcher Dina Samir Abdel-Hady

Associate Researcher Noha Mohamed Abd El Rahman

Associate Researcher  Sherihan Mohammed Al Motawakel

Associate Researcher  Mohamad Hussien Elzallat

Late Resident Shimaa Abd El Sattar Abbas

Resident Hadeel Khaled Mohammed

Resident Rawan Mohsen Mousa

Resident Arwa Mansy

Resident Lamia Madkour

Resident Amany Rezik

Resident Mohamed Hatem

Resident Gahda Rashad Abo El-Enien

Resident Afnan Mohamed Sarhan

  Field of Research

 The strategy of  Immunology Department constitutes an integrated part of the general strategy of TBRI, targeting immunodiagnosis of endemic diseases (viral and parasitic), assessment of immune response to endemic infections and their associated morbidity changes, and tackling immunological approaches for management of endemic diseases and their hepatic and urinary complications with special stress on the following targets:

I-Immunodiagnosis of endemic diseases and their consecutive complications:

A- Immunodiagnosis of parasitic infections: 

§  The detection of specific circulating anti- parasitic IgG4 improved sensitivity and specificity of immunodiagnosis of schistosomiasis, fascioliasis1, and filariasis, and can be used as screening test in endemic areas.

§  The use of affinity purified fractions of parasitic antigens e.g. a Con-A purified hydatid glycoprotein fraction, and affinity purified Fasciola worm antigen fraction, improved immunodiagnosis of human hydatidosis and fascioliasis2.

§  Production of MAbs against parasitic Antigens:

-  S. mansoni soluble egg Ag3,4

-  S. haematobium soluble egg Ag5,6

-  S. mansoni worm tegument Ag7

-  F. gigantica crude worm Ag8

-  F. gigantica ex/sec Ag8

-  W. bancrofti worm extract9

§  Establishment of antigen detection immunoassays (sandwich ELISA, dot ELISA and latex agglutination test) using our MAbs as diagnostic probes for circulating parasitic antigens in patients' sera and/ or excreta (urine or stool). The following MAb-based sandwich ELISA systems were developed showing high sensitivity and specificity rates:

§  Schistosoma antigen assay (90% sensitivity and 95% specificity)3.

§  Fasciola coproantigen assay (96% sensitivity and 97% specificity)10.

§  W. bancrofti antigen assay (95% sensitivity and 96% specificity)7, 9.

  § Development of antigen detection kit for diagnosis of active schistosomiasis and monitoring of cure on pre-commercial level.

B- Immunodiagnosis of hepatitis viruses:

§  Glial fibrillary acidic protein could represent a more useful marker than α-SMA of early activation of HSCs in CHC patients and seems to be an early indicator of hepatic fibrogenesis11.

§  Circulating miR-138 could serve as a non-invasive biomarker for the detection of early fibrosis. Also, miR-138 and miR-143 could be specific biomarkers for indicating the late stage of liver fibrosis12.

§  miR-122 might be a useful predictor for virological responses to treatment with PEG-interferon plus ribavirin therapy in patients with HCV13.

§  In Silico design and experimental validation of siRNAs targeting conserved regions of hepatitis C virus genotype 414.

C-Tissue typing:

The feasibility of using the following immunomolecular markers and biomarkers as predictive or prognostic markers for HCC:

§  HLA-DRB1*:

a)    DRB1*03 allele: predominance of this allele in HCV-infected patients reflects the  influence of this allele on susceptibility to infection.

b)      DRB1*04 and DRB1*14 allele: Identification of these alleles in HCV-infected patients stresses the importance of periodic follow up of these patients for early signs of carcinogenesis.

D-Evaluation of efficacy of medicinal herbs or drugs in malignant cell lines:


§  Hepatic carcinoma in vitro study: the methanolic extract of curcuma longa rhizomes inhibited hepatic carcinoma cell line (HEPG2) growth via apoptotic changes. This, the rhizome of Curcuma longa could be used as a natural source of anticancer drugs15.

§  The bioactive secondary metabolites of Vitex Agnuscastus extract can induce apoptosis in the H2PG cell line through caspase – activation. The antiproliferative and apoptotic properties of V. Agnuscastus extracts would suggest its use as an adjuvant in cancer therapy16.

II- Predication of malignant transformation:


A-     Assessment of the molecular and biomarkers associated with HCC:

The use of biomarkers, genetic and epigenetic markers as either predictive or prognostic markers in HCV-induced liver fibrosis and liver cancer:

  • TGF-beta1 plays a role in hepatic cell damage following HCV infection thus stressing the usefulness of this cytokine as a prognostic marker for liver cell injury. However, COX-2 is a predictive marker for malignant transformation and has a role in the early stages of hepatocarcinogenesis, but not in the advanced stages. The combined expression of both factors in HCV-related HCC suggests their synergistic action in the pathophysiology of hepatocarcinogenesis17.

§ Circulating and hepatic Fas expression in chronic hepatitis C infection illustrates the mechanism of liver injury caused by death receptors throughout the multistep process of fibrosis/carcinogenesis. Not only the higher degree of hepatic fibrosis, but also the lower expression of Fas protein, is correlated with the increased incidence of HCC18.

§ Histone H3 mRNA: Increased expression and nuclear-cytoplasmic shift denotes carcinogenic changes in chronic hepatitis C19.

§  Upregulation of Fas in chronic hepatitis C infection and of c-myc & EGFR in malignant transformation were used as progenestic markers in HCV-induced HCC. c-myc expression may obstruct the induction of apoptosis of HCC cells and lead to uncontrolled cell growth20.

§  Down-regulation of intrahepatic CD16+ and CD56+ immune cells in chronic hepatitis C virus infection and HCV-related hepatocellular carcinoma can be used as predictive and prognostic markers in HCV-induced liver cancer21.

§  The measurement of serum levels of miRNA-122a, miRNA-125a, miRNA-139, miRNA-145 and miRNA-199a can help to differentiate HCC from CHC and LC. Also, they suggest that serum miR-122 might serve as a novel and potential non-invasive biomarker for HCV-induced HCC13.

  • The combination of Sorafenib (SOR)  and Bio-A leads to synergistic cytotoxicity in the HCC cell line, HepG2, via interfering with cell cycle, enhancing mitochondrial apoptosis signaling and thus hindering cell proliferation. This study introduces a novel combination, where Bio-A synergistically enhanced the anti-proliferative and apoptotic effects of SOR in HCC cells, which could serve as a potential effective regimen for treatment22.
  • The development of an improved in silico experimental triage process to design efficacious and specific siRNAs that targeted highly conserved regions of HCV genomes. Antiviral potencies were systematically assessed in HCV genotype 1 and 2 replicon cell lines and with a patient-derived infectious HCV genotype 4 isolate.  The predicted outstanding antiviral potency of the selected siRNA confirmed a high barrier to resistance. The in silico-designed siRNA might be a valuable antiviral agent and could be considered for further development as a chronic hepatitis C therapy14.


B- Assessment of molecular and biomarkers associated with cancer   bladder:

§   The use of urinary and serum genetic biomarker as non invasive technique for early detection of malignancy and prediction of tumour behaviour.

§   The high incidence of P53 and c-erbB-2 with low expression of bcl-2 could be used as early predictive markers in chronic schistosomal cystitis.   

§   The high level of sFas in chronic cystitis patients associated with schistosomiasis could be a predictor marker for malignant transformation in those patients.

§   Angiogenic markers (VEGF bfGF, TGF-α, TGF-β) are valuable prognostic parameters especially in high risk bladder cancer patients who need continuous follow up.

§   Urinary markers (BTA + nuclear matrix protein (NMP) could be used as noninvasive biomarkers for screening of malignancy in mass population, while, hyaluronic acid + nitric oxide could detect patients at high risk for more intensive investigations.

§   Fibronectin could be used as a predictive biomarker for tumour behavior and clinical outcome as it increases with tumour invasion.

III Immunotherapy:

A. Establishment of tissue engineering unit for stem cell culture and   engraftment into hepatic patients as a new line for management of liver cell failure.

B. Myoblast cell culture as a preliminary step for their engraftment in bladder cervix sphincter as a replacement therapy for urine incontinence.

C. Establishment of a cord blood stem cell bank as a source of allogenic stem cells for treatment of complications of endemic diseases.

D. Establishment of a Defined Protocol for in vitro Trans-differentiation of Cord Blood (CB) Unrestricted Somatic Stem Cells (USSCs) into Hepatocyte-like Cells.

E. Induction of Hepatic Regeneration in an Experimental Model Using the Hepatocyte–like Cells Differentiated from in vitro Cultured CB USSCs.

1. A pilot study for Induction of hepatic regeneration in a small scale of an experimental model for hepatic fibrosis/cirrhosis in mice infected with Schistosoma mansoni cercariae, and CCL4 induced cirrhotic hamsters26.      

2. Induction of hepatic regeneration in our planned experimental models guided by the results of the pilot study.

3. Induction of hepatic regeneration in a CCl4 model using hepatocyte-cells from USSCs cultured and differentiated in either 2D or 3D culture systems.

4. Studying the effect of transplantation of hepatocyte-like cells in the experimental model on liver function and biochemical markers of liver fibrosis, liver pathology, as well as repopulation of the liver by the newly transformed hepatocyte-like cells.


F.    Establishment of the Use of CB-USSCs as a Future Candidate for Cellular  Therapy of Hepatic Failure on Experimental Level.


G.   Gene therapy:

§  The modulation of the EMT markers could be promising as potential therapeutic agents. Further searching for the genetic factors that control the expression of EMT markers would be a powerful strategy to treat liver fibrosis at the genetic level either through the arrest of EMT or the introduction of EMT23.

§  The target genes of the microRNAs control almost all the hallmarks of liver cancer which can be used as therapeutic targets in cancer treatment24.

§  New ultrastructure observations which may be of value in predicting HCC and identifying the appropriate patient for surveillance. This finding has supported the speculation of the malignant potentiality of liver stem/progenitor cell and the impact of HSCs on this process25.

  Running Techniques

1)  Immunodiagnostics laboratory 

·        Diagnosis of Parasitic Infection (ELISA):

  Detection of circulating anti-schistosome antibodies.

  Detection of circulating schistosome antigen.

   Detection of circulating anti-Fasciola hepatica antibodies.

   Detection of circulating anti-E. granulosus antibodies.

·        Detection of Autoantibodies:

  Anti-nuclear antibodies.

·        Detection of Hepatitis Markers.

 Detection of HB surface antigen.

  Detection of circulating anti-HCV antibodies

·        Enzyme-linked immune-electrophoresis transfers blot (EITB).

·        SDS-polyacrylamide gel electrophoresis (SDS- PAGE).

·        Immuno-diffusion.

·        Immunofluorescence.

·        Immunohistochemistry and immunolocalization.

2)  Tissue engineering units:

·        Isolation of different types of stem cells (MSCs & USSCs) from bone marrow and cord blood.

·        Stem cells characterization by flowcytometry, and gene expression analysis by real-time PCR.

·        Induction of differentiation of stem cells into osteogenic, chondrogenic and adipogenic lineages.

·        Experimental treatment of hepatic fibrosis (induced by CCl4 and Schistosoma infection) by stem cells. 

3)  Monoclonal antibody production unit:

·        Tissue culture techniques:

  Basics of tissue culture.

  Monoclonal antibody production by hybridoma technology against different parasitic antigens (Schistosoma mansoni, Schistosoma haematobium, Fasciola, Filaria, and Hydatid). 

·        Characterization of monoclonal antibody:

   Isotype characterization.

    SDS and Immunoblotting.

    Polyclonal antibody production in rats.

   Mononuclear cell separation.  


·        Purification:

     Ammonium sulfate.

    Boric acid.

    Conjugation of MAb by HRP.

   Development of immunodiagnostic kits (ELISA) for endemic diseases using our own monoclonal antibodies. 

4)  Molecular unit:

   Basics of molecular biology.

    RNA, DNA and microRNA extraction.

    DNA hypo/ hyper-methylation.

     Gene expression analysis by real-time PCR.

   Detection of  serum epigenetics markers using RT-PCR

5)  Experimental animal unit:

Establishment of HCC murine model.

  Laboratory Structure and Facilities

The Immunology Department consists of a Central Immunology Research Laboratory and a "Tissue Culture Unit".

The Central Immunology Research Laboratory consists of the following units:

-  Immunodiagnostics laboratory (ELISA, immunofluorescent technique, agglutination tests, etc.).

-  Immunochemistry laboratory (electrophoresis, immunoelectrophoresis, SDS-PAGE, immunoblotting, Isoelectric focusing,PCR, affinity and ion-exchange chromatography, etc.).

-   The Tissue Culture Unit includes:

·        A preparatory laboratory.

·        Tissue engineering units.

·        GMP unit for stem cells.

·        Monoclonal production unit.

-         Molecular unit includes:

  • Real-time PCR.

List of the most important equipment:

-      Laminar flow cabinets.

-      CO2 incubators (5%).

-      Liquid nitrogen containers and controlled rate freezing apparatus.

-      Microscopes (inverted and fluorescent).

-      DNA and protein electrophoresis and electroelution systems.

-      Transblot cell.

-      PCR apparatus.

-      UV trans-illuminator and UV camera.

-      ELISA reader.

-      Autoclave, ovens, incubators, shaking incubators and water baths.

-      Vertical and horizontal deep freezers (-20 degrees Celsius and -40 degrees Celsius).

-      Centrifuges (cooling and ultracentrifuge).

-      Bi-distillator.

-      Digital balances.

-      Electric tissue homogenizer, sonicator and lyophilizer.

-      Two computers are available for research work at the Immunology Department.


  Training facilities

 Fields of training:

-  Monoclonal antibody production.

-  Molecular immunology.

- Tissue culture.

- Stem cells.

- Epigenetic field.

-Serodiagnostic techniques (ELISA,Immunoblotting).


The Immunology Department at Theodor Bilharz Research Institute is considered as one of the Centers of Excellency for the production of monoclonal antibodies and their application in immunoassays for early diagnosis of active parasitic infection and monitoring of cure.


The research team at the Immunology Department, TBRI, is highly qualified and has vast experience and skills in the field of immunodiagnosis, characterization and purification of proteins, cell cloning, production, characterization and applications of monoclonal antibodies in immunoassays. Several international projects with relevant technologies have been carried out at the Immunology Department during the last few years.

  Scope of Services

 1-    Diagnosis of Parasitic Infection (ELISA)

- Detection of circulating anti-schistosome antibodies.
- Detection of circulating schistosome antigen.
- Detection of circulating anti-Fasciola gigantica antibodies.
- Detection of circulating anti-E. granulosus antibodies.


2-    Detection of Autoantibodies
- Anti-nuclear antibodies. (ELISA)
- Anti-DNA antibodies.
- Anti-smooth muscle antibodies.
- Anti-neutrophil antibodies.
- Anti-mitochondrial antibodies.
- Liver/kidney microsomal antibodies.


3-    Detection of Hepatitis Markers (ELISA)
- Detection of circulating anti-HAV antibodies.
- Detection of HB surface antigen.
- Detection of circulating anti-HBc antibodies (IgM & IgG)
- Detection of HBe antigen.
- Detection of circulating anti-HBe antibodies. 
- Detection of anti-HBs antibodies
- Detection of circulating anti-HCV antibodies


   4- Detection of Tumor Markers (ELISA)
          - CA 19.9
          - CA 50
          - CA 242
          - CA 15.3


The Project of the Immunology Staff Members in the Last Ten Years is the Followings Projects:

  • Development of MAb labeled nanoparticles-based immunostrip assay for early detection of bladder cancer biomarkers in Egyptian patients. PI: Prof. Manal Kamel (2020-2022), funded by Academy of Scientific Research and Technology, Science and Technology Center (STC), National Strategy for Genetic Engineering and Biotechnology (Phase iii: Applications & Products).
  • TBRI Biobank for Liver Diseases: Research Translation and Precision Medicine in Hepatology. PI: Mona Zoheiry (2020-2023), funded by STDF, STDF Grants for Accredited Centers of Scientific Excellence (STDF-ACSE).
  • Epigenetic regulation of circulating cancer stem cell in HCV-induced hepatocellular carcinoma. PI: Mona Zoheiry (2020-2022), funded by STDF, Basic and Applied Research Grant (BARG), Call 6.
  • Polymer Nanoparticle Mediated Delivery of MicroRNA: A Novel Potential Therapeutic Tool for Hepatocellular Carcinoma in an Experimental Model. PI: Prof. Eman El-Ahwany (2019-2021), funded by Science Technology Development Fund (STDF), Basic and Applied Research Grant (BARG), Call 4.
  • Long Non-Coding RNA: An Innovative Therapeutic Tool for Hepatocellular Carcinoma in vitro and in vivo. PI: Prof. Eman El-Ahwany (2019-2021), funded by STDF, Innovative Grant, Call 6.
  • Circulating MicroRNAs as Diagnostic and Prognostic Tools in HCV-induced Liver Fibrosis. PI: Prof. Mona Zoheiry (2017-2019), funded by TBRI.
  • Circulating cancer stem cells markers: Diagnostic tools in chronic/cirrhotic viral hepatitis patients. ID: 107 Diagnosis, PI: Dr. Marwa Hassan (2018-2020), funded by TBRI.
  • Potential effect of bone marrow-derived stem cells for treatment of experimentally induced ulcerative colitis in animal model. ID: 125 Therapy, PI: Dr. Shimaa Attia (2018-2020), funded by TBRI.
  • Expansion of anti-Schistosomamansoni secretory hybridomas in chemically defined serum free culture as a reliable source for monoclonal antibodies. ID: 27 Biotechnology, PI: Prof. Kesmat Maher (2018-2020), funded by TBRI.
  • Development of easy to use and affordable biomarkers as diagnostics for types II and III diseases. PI: Prof. Dr. Hanan El-Baz (2016 – 2019), funded by World Health Organization (WHO).
  • Project Based Training and Fellowship on Development, Production and Access to Diagnostics. PI: Prof. Dr. Hanan El-Baz  (2015 – 2019), funded by African Network for Drug & Diagnostic Innovation (ANDI).
  • Effect of repeated passaging and cell density on proliferation and differentiation potential of cord blood Mesenchymal stem cells.  ID: 11 Biotechnology, PI: Prof. Kesmat Maher, (2014- 2018), funded by TBRI.
  • The differentiation potential of human cord blood- derived mesenchymal stem cells into functional hepatocyte-like cells on nanofibrous scaffold. ID: 12 Biotechnology, PI: Prof. Zeinab Demerdash, (2014-2018), funded by TBRI.
  • Transplantation of Hepatogenic Differentiated Mesenchymal Stem   Cells versus Adult Hepatocytes in Experimental Chronic Liver Insult Model: A Comparative Study. ID: 13 Biotechnology, PI: Prof. Hanan El-Baz, (2013-2018), funded by TBRI.
  • Prediction of miRNA Target Genes Involved in Liver Cancer Pathways and its Validation. ID: 14 Biotechnology, PI: Prof. Faten Nagy (2014-2019), funded by TBRI.
  • Mesenchymal stem cells with or without targeted gold coated magnetic nanoparticles as a novel therapeutic tool in hepatocellular carcinoma murine model: A pilot study. ID: 19 Biotechnology, PI: Prof. Wafaa A. Mansour (2014-2019), funded by TBRI.
  • Novel Diagnostic and Therapeutic Tools in Murine Model of Hepatocellular Carcinoma: A Pilot Study. ID: 8 Biotechnology, PI: Prof. Eman El-Ahwany (2012-2017), funded by TBRI.
  • Anticancer Potential of Some Medicinal Herbs on both Hepatocellular Carcinoma and Squamous Cell lines. ID: 98 Therapy, PI: Prof.  Hanaa Hassanein, (2012-2015) funded by TBRI.
  • Circulating markers related to influx of the liver with extrahepaticmyo-fibroblast progenitor cells as predictors of HCV-induced hepatic fibrosis and carcinogenesis. ID: 86 Diagnosis, PI: Prof. Mona Zoheiry (2011-2017), funded by TBRI.
  • The Generation of Cord Blood-Derived Unrestricted Somatic Stem Cells and Their Differentiation into Hepatocyte-like Cells Pave the Way for Liver Regeneration.  PI: Prof. Zeinab Demerdash, (2010-2015), funded by STDF (Target call, HCV Call).
  • Hepatogenic Differentiation Potentials of Human Mesenchymal   Stem Cells: An in-vitro Study. ID: 5 Biotechnology, PI: Prof. Hanan El-Baz (2010-2018), funded by TBRI.
  • Processing and Cryopreservation of Cord Blood: A preliminary Step Towards the Establishment of TBRI National Stem Cell Bank. ID: 3 Biotechnology, PI: Prof. Zeinab Demerdash (2009-2014), funded by TBRI.
  • Autologus Hematopoietic Stem Cells in The Treatment of End-Stage Liver Disease: A Pilot Clinical Trial conducted in TBRI. ID: 2 Biotechnology, PI: Prof. Hanan El-Baz (2009-2015), funded by TBRI.
  • Culture of hybridoma cell lines in serum- free media using spinner flasks: A step forward for large scale production of monoclonal antibodies of high quality. ID: 4 Biotechnology, PI:  Prof. Faten Salah, (2009-2012), funded by TBRI.
  • Processing and Cryopreservation of Cord Blood: A preliminary Step Towards the Establishment of TBRI National Stem Cell Bank. ID: 3 Biotechnology, PI: Prof. Zeinab Demerdash (2009-2014), funded by TBRI.
  • Pilot Study of Anticancer Potential of Some Herbal Medicine. ID: 89 Therapy, PI: Prof. Hanaa Hassanein (2008-2010), funded by TBRI.


Cooperative Projects

  • A novel nanotechnology -based approach for the rapid diagnosis of infectious diseases using nano-chip. PI: Prof. Dr. Ibrahim Rabie (Parasitology Department), Participant: Dr. Shimaa Attia (2020-2022), funded by STDF, Innovative Grant, Call 6.
  • The antistress ability of medicinal plants on cultured stem cells. PI: Asmaa Salah (Medicinal Chemistry Department), Dr. Shimaa Attia (2020-2022), funded by TBRI.
  • Water borne diseases risk associated with human activities in River Nile in the area of Greater Cairo with special emphasis on Scistosomiasis, Escherichia coli, Cryptosporidium and Giardia. ID: 104 Control, PI: Prof. Hanaa EL-Khiat (Environmental Research Department), Participant: Dr. Shimaa Attia (2018-2020), funded by TBRI.
  • Assessment of potential synergistic or antagonistic toxicity mechanisms during co–exposition of in vitro models towards cerium dioxide nanoparticles and environmental chemicals/ pharmaceuticals. PI: Prof. Mohamed Shemis (TBRI), Participants: Prof. Eman El-Ahwany and Dr. Marwa Hassan (2018-2020), funded by the German Egyptian Research Fund (GERF).
  • DNA Methylation and microRNA Crosstalk as epigenetic Prognostic Biomarker for HCV Induced Hepatocellular Carcinoma. ID: 24 Biotechnology, PI: Prof. Faiza El-Essawy, (Hematology Department), Participant: Prof: Mona Zoheiry (2017-2019), funded by TBRI.
  • Long non-coding RNA as a novel non-invasive diagnostic tool for HCV-induced hepatocellular carcinoma. ID: 23 Biotechnology, PI: Prof. Faiza El-Essawy (Hematology Department), Participant: Prof. Eman El-Ahwany (2017-2019), funded by TBRI.
  • SAT-2, SAT-3, ALU and LINE1 hypo methylation as an early diagnostic and prognostic marker for HCV related hepatocellular carcinoma. ID: 100 Diagnosis, PI: Prof. Moataz Siam (Gastroenterology Department), Participants: Prof. Eman El-Ahwany & Dr. Marwa Hassan (2015-2017) funded by TBRI.
  • MiRNAs as a novel therapeutic tool in HCV-induced liver fibrosis. PI: Prof. Suher Zada (AUC), CO-PI: Prof. Eman El-Ahwany (2011-2012), funded by the American University in Cairo (AUC).
  • Theodor Bilharz into European research Area" THEBERA” project. PI: Sanaa Botros, Participant: Prof. Hanan El-Baz (2010-2015), funded by European Union (EU), as an ERA-WIDE FP7.
  • Nanoparticles as a Delivery System for Targeting Schistosmiasis and Fascioliasis: A pilot study.  PI: Prof. Suher Zada (AUC) & Prof: Ibrahim Rabie (TBRI), CO-PI: Prof. Eman El-Ahwany. Funded by the Science Technology Research Centre (STRC), the American University in Cairo and TBRI, (2010-2011).
  • A therapeutic trial for HCV infection using small interfering RNA (siRNA) targeting the viral genome.  PI: Prof. Mahmoud El Hefnawi (National research Centre), Participant: Prof. Eman El-Ahwany (2010-2014), funded by Technology Development Fund (STDF), Target Call HCV.



Publications in the Last Ten Years

Shawki E, El-Beih NM, El-Hussieny EA, EL-Ahwany E, Hassan M, Zoheiry M (2020). Effects of Free and Nanoparticulate Curcumin on Chemically-Induced Liver Carcinoma in Animal Model. Archives of Medical Science, Online publish date: 2020/03/17.

El Baz H, Demerdash Z, Kamel M, Hammam O,  Abdelhady  D, Mahmoud S, Salah F, Hassan S, Atta S,  Riad N,  Gaafar T (2020). Induction of Hepatic Regeneration in an Experimental Model Using Hepatocyte-Differentiated Mesenchymal Stem Cells. Cellular Reprogramming, 22: 1-13.

El-Razek SEA, El-Gamasy SM, Hassan M, Abdel-Aziz MS, Nasr SM (2020). Transition metal complexes of a multidentate Schiff base ligand containing guanidine moiety: Synthesis, characterization, anti-cancer effect, and anti-microbial activity. Journal of Molecular Structure 1203: 127381.

Demerdash Z, El Baz H, Ali N, Mahmoud F, Mohamed S, Khalifa R, Hassan M, Shawky S (2020). Cloning of Human Cord Blood-Mesenchymal Stem Cells for Isolation of Enriched Cell Population of Higher Proliferation and Differentiation Potential. Molecular Biology Reports 47: 3963-3972.

Fawzy Roshdy, Mohamed MS Farag, Eman El-Ahwany, Ola Mahmode, Adel A Mousa, Mohamed El Talkawy, Faiza Essawy (2020). Long non-coding RNA HOTAIR and HOTTIP as potential biomarkers for hepatitis C virus genotype 4-induced hepatocellular carcinoma. Egyptian Journal of Medical Human Genetics. 21 (1): 1-13.

Gamal Ramadan, Marwa M Mohammed, Mona K Zoheiry, Nadia El-Beih (2020). Whey protein concentrate and lactoferrin alleviated anaemia, immunotoxicity, and biochemical alterations in a mouse model of early hepatocarcinogenesis. International Dairy Journal, 102: 104603

Eman El-Ahwany, Soheir S Mansy, Mona Zoheiry, Lobna Mourad, Soheir Mahmoud, Hoda Abu-Taleb, Moataz Hassanien, Marwa Hassan (2020). MicroRNA-195 vector influence on the development of gradually induced hepatocellular carcinoma in murine model.  Ultrastructural Pathology, 44 (2): 203-210.

Sameh Saber, Amal MH Ghanim, Eman El-Ahwany, Eman M Abd El-Kader (2020). Novel complementary antitumour effects of celastrol and metformin by targeting IκBκB, apoptosis and NLRP3 inflammasome activation in diethylnitrosamine-induced murine. Cancer Chemotherapy and Pharmacology, 85 (2): 331-343.

Eman GE El-Ahwany, Lobna Mourad, Mona MK Zoheiry, Hoda Abu-Taleb, Marwa Hassan, Raafat Atta, Moataz Hassanien, Suher Zada (2020). MicroRNA-122a as a non-invasive biomarker for HCV genotype 4-related hepatocellular carcinoma in Egyptian patients. Archives of Medical Science, 15 (6): 1454-1460.

Hend Okasha, Hassan M, Tarek Aboushousha, Safia Samir (2019). Effect of Interferon-Beta (IFN-β) on Tumor suppressor and Apoptotic Markers in Hepatocellular Carcinoma Cell Line. International Journal of Research in Pharmaceutical Sciences, 10(4): 2936-2943.

Rady E El-Araby, Mahmoud A Khalifa, Mona M Zoheiry, Manal Y Zahran, Mohamed I Rady, Raafat A Ibrahim, Mohamed D El-Talkawy, Faiza M Essawy (2019). CDH1 gene as a prognostic biomarker in HCV (genotype 4) induced hepatocellular carcinoma in the Egyptian patients. Gene Reports, 16: 100452.

Marwa M Mohammed, Gamal Ramadan, Mona K Zoheiry, Nadia M ElBeih (2019). Antihepatocarcinogenic activity of whey protein concentrate and lactoferrin in diethylnitrosaminetreated male albino mice. Environmental toxicology, 34 (9): 1025-1033.

Mahmoud FS, Demerdash Z, Elmotawakel S, Hassan S, Hendawy M, Atta S, Shawky S, Alkhateeb E, Hassenein H (2019). Serum low replacement medium versus serum rich replacement medium for production of Anti-Schistosoma Monoclonal antibody: A comparative study. Clinical Epidemiology and Global Health, 8(2): 423-427.

Kamel M, Salah F, Demerdash Z, Maher S, Atta S, Badr A, Afifi A, El-Baz H (2019). Development of a new lateral-flow imunochromatographic strip using colloidal gold and mesoporous silica nanoparticles for rapid diagnosis of active Schistosomiasis. Asian Pacific Journal of Tropical  Biomedicine, 9: 315-322.

Rady E El-Araby, Mahmoud A Khalifa, Mona M Zoheiry, Manal Y Zahran, Mohamed I Rady, Raafat A Ibrahim, Mohamed D El-Talkawy, Faiza M Essawy (2019). The interaction between microRNA-152 and DNA methyltransferase-1 as an epigenetic prognostic biomarker in HCV-induced liver cirrhosis and HCC patients. Cancer gene therapy, 1: 1-12.

Ghanem LY, Mansour IM, Abulata N, Akl MM, Demerdash ZA, El Baz HG, Mahmoud SS, Mohamed SH, Mahmoud FS, Hassan ASM (2019). Liver macrophage depletion ameliorates the effect of mesenchymal stem cell transplantation in a murine model of injured liver. Scientific Reports, 9(1): 35.

El-Lakkany NM, El-Maadawy WH, Seif El-Din SH, Saleh S, Safar MM, Ezzat SM, Mohamed SH, Botros SS, Demerdash Z, Hammam OA (2019). Antifibrotic effects of gallic acid on hepatic stellate cells: In vitro and in vivo mechanistic study. Journal of Traditional and Complementary Medicine, 9(1): 45-53.

Sameh Saber, Rania M Khalil, Walied S Abdo, Doaa Nassif, Eman El-Ahwany (2019). Olmesartan ameliorates chemically-induced ulcerative colitis in rats via modulating NFκB and Nrf-2/HO-1 signaling crosstalk. Toxicology and applied pharmacology, 364: 120-132.

El Baz H, Demerdash Z, Kamel M, Atta S, Salah F, Hassan S, Hammam O, Khalil H, Bayuomi A (2019). Potentials of differentiated human cord blood derived unrestricted somatic stem cells in treatment of liver cirrhosis. Experimental & Clinical Transplantation, 17: 251-258.

Attia H. Atta, Samar M. Mouneir, Soad M. Nasr, Doaa Sedky, Amany M. Mohamed, Shimaa A Atta, Hassan Mohamed Desouky (2019). Phytochemical studies and anti-ulcerative colitis effect of Moringa oleifera seeds and Egyptian propolis methanol extracts in a rat model. Asian Pacific Journal of Tropical Biomedicine; 9(3): 98-108.

Heba KM Khalil, Mona Zoheiry, Nora N Kamel, Tarek Aboushousha, Eman El-Ahwany, Hoda A Taleb, Mohamed D El-Talkawi, Ali Abdel Rehim, Noha M Khalil, Marwa Hassan, Ahmed Y Montasser (2018). Hepatocellular expression of epithelial–mesenchymal transition markers in a sample of hepatitis C virus-infected Egyptian patients. Egyptian Journal of Pathology, 38 (2): 234-240.

Saber S, Mahmoud AAA, Goda R, Helal NS, El-Ahwany E, Abdelghany RH (2018). Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B. Toxicology Letters, May 31, 295: 32-40.

Amanda Abdel-Al, Eman El-Ahwany, Mona Zoheiry, Marwa Hassan, Amged Ouf, Hoda Abu-Taleb, Ali Abdel Rahim, Mohamed Darwish El-Talkawy, Suher Zada (2018). miRNA-221 and miRNA-222 are promising biomarkers for progression of liver fibrosis in HCV Egyptian patients. Virus research, 253: 135-139.

Malak Nabil Amin, Ashraf Okba, Abeer Abdel Hamid Eissa, Mohamed Asharf Ibrahim, Mona Kamel Zoheiry, Abu Taleb, Hoda Mohamed Aly (2018). Th17 and tregulatory cells in type2 diabetic nephropathy.  Journal of the Egyptian Society of Parasitology, 48(3): 605-613.

Sameh Saber, Amr Mahmoud, Noha Helal, Eman El-Ahwany, Rasha Abdelghany (2018). Liver protective effects of renin-angiotensin system inhibition have no survival benefits in hepatocellular carcinoma induced by repetitive Administration of Diethylnitrosamine. Macedonian journal of medical sciences, 6(6): 955.

Lobna Mourad, Eman El-Ahwany, Mona Zoheiry, Hoda Abu-Taleb, Marwa Hassan, Amged Ouf, Ali Abdel Rahim, Moataz Hassanien, Suher Zada (2018). Expression analysis of liver-specific circulating microRNAs in HCV-induced hepatocellular carcinoma in Egyptian patients. Cancer biology & therapy, 19 (5):  400-406.

Sameh Saber, Amr AA Mahmoud, Noha S Helal, Eman El-Ahwany, Rasha H Abdelghany (2018). Renin–angiotensin system inhibition ameliorates CCl4-induced liver fibrosis in mice through the inactivation of nuclear transcription factor kappa B. Canadian journal of physiology and pharmacology, 96 (6): 569-576.

Kamel MM, El-Baz HG, Demerdash Z, Hassan S, Salah F, Mansour WA, Hammam O, Atta S, Bayoumi A, Hassan M, Mahmoud S (2018). Cord blood-derived mesenchymal stem cells with hepatogenic differentiation potential ameliorate chronic liver affection in experimental models. Advances in Clinical and Experimental Medicine 27(10):1329-1339.

Soheir S Mansy, Eman El-Ahwany, Soheir Mahmoud, Sara Hassan, Mohammed I Seleem, Amr Abdelaal, Ahmed H Helmy, Mona K Zoheiry, Ahmed S AbdelFattah, Moataz H Hassanein (2017). Potential ultrastructure predicting factors for hepatocellular carcinoma in HCV infected patients. Ultrastructural pathology, 41 (3): 206-226.

S Saber, AA Mahmoud, NS Helal, E El-Ahwany, RH Abdelghany (2017). Losartan, an angiotensin-II type 1 receptor blocker, attenuates CCl4-induced liver fibrosis with a positive impact on survival in mice. World J Pharm Pharm Sci., 5 (12): 121-126.

Khalifa RH, Labib DA, Kamel MA, Shahin RMH, Bahgat DMR, Riad NM, El Khateeb E, El-deeb AM, Hassan M (2017).  Role of ApoB-516C/T promoter gene polymorphism in the risk of Hepatitis C Virus infection in Egyptian patients and in gender susceptibility. Journal of Medical Virology, 89(9): 1584-1589.

El Baz H, Demerdash Z, Kamel M, Atta S, Salah F, Hassan S, Hammam O, Khalil H, Meshaal S, Raafat I (2017). Transplant of Hepatocytes, Undifferentiated Mesenchymal Stem Cells, and In Vitro Hepatocyte-Differentiated Mesenchymal Stem Cells in a Chronic Liver Failure Experimental Model: A Comparative Study. Experimental & Clinical Transplantation, 16: 81-89.

Youssef MM., Tolba M., Badawy NN, Andrew W. Liu, El-Ahwany E, Khalifa AE, Zada S, Abdel-Naim AB (2016). Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells. Scientific Reports, 6: 30717.

Abdel-Lateef E, Hammam O, Mahmoud FS, Atta SA, El-SayedMM, Hassenein HI (2016). Induction of apoptosis in HepG2 by Vitexagnus-castus L. leaves extracts and identification of their active chemical constituents by LC-ESI-MS. Asian Pacific Journal of Tropical Disease, 6(7): 539-548.

Abdel-Lateef E, Mahmoud F, Hammam O, El-Ahwany E, El-Wakil E, Kandil S, Abu-Taleb H., El-Sayed M, Hassenein H (2016). Bioactive chemical constituents of Curcuma longa L. rhizomes extract inhibit the growth of human hepatoma cell line (HepG2).  Acta Pharmaceutical, 66: 1-13.

El-Ahwany E, Nagy F, Zoheiry M, Shemis M, Nosseir M, Taleb HA, El Ghannam M, Atta R, Zada S (2016). Circulating miRNAs as predictor markers for activation of hepatic stellate cells and progression of HCV-induced liver fibrosis. Electron Physician, 8(1): 1804-1810.

El-Hefnawi M, TaeKyuKim, Kamar M, SaehongMin, Hassan N, El-Ahwany E, Heeyoung Kim, Zada S, Amer M, Marc P. Windisch (2016). In Silico Design and Experimental Validation of siRNAs Targeting Conserved Regions of Multiple Hepatitis C Virus Genotypes. PLOS ONE, 11(7): e015921.

Zoheiry M, El-Ahwany E (2015). Role of epithelial mesenchymal transition in hepatic fibrogenesis. Journal of the Egyptian Society of Parasitology, 45(2): 357 -364. 

Abdel-Ghany R, Rabia I, El-Ahwany E, Saber S, Gamal R, Nagy F, Mahmoud O, Hamad RS, Barakat W (2015). Blockade of pge2, pgd2 receptors confers protection against prepatent Schistosomiasis mansoni in mice. Journal of the Egyptian Society of Parasitology, 45(3): 511-520.

Ahwany EG, Nagy FM, Zoheiry MK, El Ghannam MT, El Khashab MN, Ahmadi W, El-Refaiy M, Zada SK, Shaker ZA (2015). Role of T regulatory cells in chronic HCV infected Egyptian patients and their impact on the response to pegylated interferon therapy. Journal of the Egyptian Society of Parasitology, 45(2): 345-356.

Maher k, El-Baz H, Demerdash Z, Shawky S, Hassan M, Mohamed S, Mahmoud F, Khalil M, Hammam O,  Taha T (2015). Long term culture of CB-MSCs deteriorates their stemness nature through a series of biomolecular changes. Global Journal of Medicine and Medical Sciences, 3(1):097-107.

Ghinolfi D, El Baz HG, Borgonovi E, Radwan A, Laurence O, Sayed HA, De Simone P, Abdelwadoud M, Stefani A, Botros SS, Filipponi F (2014). A model for Southern Mediterranean research institute self-assessment: a SWOT analysis-based approach to promote capacity building at Theodor Bilharz Research Institute in Cairo (Egypt). Arab Journal of Gastroenterology, 15(3-4): 92-97.

Amer M, Elhefnawi M, El-Ahwany E, Awad AF, Gawad NA, Zada S, Tawab FM (2014). Hsa-miR-195 targets PCMT1 in hepatocellular carcinoma that increases tumor life span. Tumour Biology, 35(11): 11301-11309.

Demerdash Z, Mohamed S, Hendawy M, Rabia I, Attia M, Shaker Z, Diab TM (2013). Monoclonal antibody-based dipstick assay: A reliable field applicable technique for diagnosis of Schistosoma mansoni infection using human serum and urine samples. Korean Journal of Parasitology, 51(1): 93-98.

El-Ahwany E, Bauiomy IR, Nagy F, Zalat R, Mahmoud O, Zada S (2012). T regulatory cell responses to immunization with a soluble egg antigen in Schistosoma mansoni-infected mice. Korean Journal of Parasitology, 50(1): 29-35.

El-Ahwany E, Rabia I, Nagy F, Zoheiry M, Diab T, Zada S (2012). Protective role of purified cysteine proteinases against Fasciola gigantica infection in experimental animals. Korean Journal of Parasitology, 50(1): 45-51.

Demerdash Z., Diab T, Aly I R, Mohamed S, Mahmoud F, Zoheiry  M, Mansour W, Mohy E, Attia M, El-Bassiouny A (2011). Diagnostic efficacy of monoclonal antibody-based sandwich enzyme linked immunosorbent assay (ELISA) for detection of Fasciola gigantica excretory/secretory antigens in both serum and stool. Parasite Vectors, 4: 176.

Elkhafif N, El Baz H, Hammam O, Hassan S, Salah F, Mansour W, Mansy S, Yehia H, Zaki A, Magdy R (2011). CD133(+) human umbilical cord blood stem cells enhance angiogenesis in experimental chronic hepatic fibrosis. Acta Pathologica, Microbiologica, et Immunologica Scandinavica, 119(1): 66-75.

Hassanein H, El-Ahwany E, Salah F, Hamaman O, Refai L, Hamed M (2011).  Extracts of five medicinal herbs induced cytotoxicity in both hepatoma and myeloma cell lines. The Journal of Cancer Science and Therapy, 3: 10-17.

Rabia I, El-Ahwany E, El-Komy W, Nagy F (2010). Immunomodulation of hepatic morbidity in murine schistosomiasis mansoni using fatty acid binding protein. Journal of American science, 6 (7): 170-176.

Zakaria S, Youssef M, Moussa M, Akl M, El-Ahwany E, El-Raziky M, Mostafa  O, Helmy AH, El-Hindawi A (2010). Value of alpha-smooth muscle actin and glial fibrillary acidic protein in predicting early hepatic fibrosis in chronic hepatitis C virus infection. Archives of Medical Sciences, 6(3): 356-365.